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Carthamus tinctorius (CT), also named saﬄower, is a traditional Chinese medicine widely used to improve blood circulation. CT
also has been studied for its antitumor activity in certain cancers. To investigate the eﬀects of CT on the dendritic cell (DC)-based
vaccine in cancer treatment, cytokine secretion of mouse splenic T lymphocytes and the maturation of DCs in response to CT
were analyzed. To assess the antitumor activity of CT extract on mouse CD117+ (c-kit)-derived DCs pulsed with JC mammal
tumor antigens, the JC tumor was challenged by the CT-treated DC vaccine in vivo. CT stimulated IFN-γ and IL-10 secretion of
splenic T lymphocytes and enhanced the maturation of DCs by enhancing immunological molecule expression. When DC vaccine
was pulsed with tumor antigens along with CT extract, the levels of TNF-α and IL-1β were dramatically increased with a dose-
dependent response and more immunologic and co-stimulatory molecules were expressed on the DC surface. In addition, CT-
treatedtumorlysate-pulsedDCvaccinereducedthetumorweightintumor-bearingmiceby15.3%morethantumorlysate-pulsed
DC vaccine without CT treatment. CT polarized cytokine secretion toward the Th1 pathway and also increased the population of
cytotoxic T lymphocytes ex vivo. In conclusion, CT activates DCs might promote the recognition of antigens and facilitate antigen
presentation to Th1 immune responses.
1.Introduction
Carthamus tinctorius (CT), also named saﬄower, is a tra-
ditional Chinese medicine widely used to improve blood
circulation [1], extending the coagulation time in mice and
exhibiting a signiﬁcant antithrombotic eﬀect [2]. However,
CT is used not only for its traditional medicinal purposes
but is also eﬀective for treating breast cancer [3]. The
oil extracted from the seed of CT is reported to contain
alkane-6,8-diols, which have the activity to inhibit 12-O-
tetradecanoylphorbol-13-acetate-induced tumor promotion
in two-stage carcinogenesis in mouse skin. In addition, N-
feruloylserotonin and N-(p-coumaroyl) serotonin strongly
inhibit the melanin production of Streptomyces bikiniensis
and B16 melanoma cells [4, 5]. These compounds are
suggested to have potential antitumor eﬀects. In addition,
CT also is neuroprotective for cerebral ischemic injury in
vivo and in vitro [2]. Recently, N-(p-coumaroyl)serotonin
and N-(p-coumaroyl)tryptamine, active ingredients in CT,
were shown to strongly inhibit the production of proin-
ﬂammatory cytokines (IL-1α,I L - 1 β, IL-6, IL-8 and TNF-
α) from lipopolysaccharide-stimulated human monocytes
[6]. Notably, extracts of CT exhibit a vast diversity of
bioactivities, including immunomodulation, anti-infarction,
antiallergic, anti-inﬂammatory and antiestrogenic eﬀects, as
well as functioning as a hemostatic agent to promote blood
coagulation. Table 1 summarizes the diverse bioactivities
of CT and delineates the therapeutic implications for this
potent herbal medicine.
Dendriticcells(DCs)areprofessionalantigen-presenting
cells that stimulate immune responses by presenting endoge-
nous or exogenous antigens to T-helper lymphocytes [31].
Immature DCs can be diﬀerentiated from monocytes and
bone marrow progenitor cells by treatment with GM-CSF
andIL-4[32,33],afterwhichthecellsgainstrongphagocytic
activity but not antigen presentation activity. Immature DCs
are stimulated with maturation signals to express more
surface immunological molecules (such as CD86, CD80,2 Evidence-Based Complementary and Alternative Medicine
Table 1: The biological activities and therapeutic indications for extracts of CT.
Plant part Possible active
ingredients Biological activities and clinical relevance Literature source
Flower
Saﬄor yellow
Inhibitory eﬀects on the production of antibody and delayed-type
hypersensitivity reaction in vivo; and the responsiveness of mixed
lymphocyte reaction and production of IL2 in vitro
Lu et al. [7]
Antilipid peroxidation eﬀects Jin et al. [8]
Triterpene Anti-inﬂammatory activity against
12-O-tetradecanoylphorbol-13-acetate-induced inﬂammation Akihisa et al. [9]
Polysaccharides Antitumor activities through toll-like receptor 4/NF-κBp a t h w a yi n
the cell assay Ando et al. [10]
Hydroxysaﬄor yellow A Anti-thrombotic and -infraction eﬀects and as a neuroprotective
agent against cerebral ischemic damage
Wang et al. [1]
Zhu et al. [2]
Zhang et al. [11]
Zhu et al. [12, 13]
Carthamin, saﬄower
yellow Antiproliferative and pro-apoptotic activities in hepatic stellate cells Chor et al. [14]
Reduction of cerebral infarction volume along with increase of bcl-2
and decrease of caspase-3 Luo et al. [15]
Improving functions of cardiac contraction and dilation, increasing
coronary blood ﬂow and strengthening the bcl-2 protein expression Zhang and Jiang [16]
Water soluble
substances Cytotoxic eﬀects on the rat nervous cells and may cause teratogenesis Nobakht et al. [17]
Antimycotic properties especially against Aspergillus fumigatus Blaszczyk et al. [18]
Seed
Oil extracts Antitumor eﬀects in a skin and beast cancer animal model and in a
melanoma cell assay system
Loo et al. [3]
Roh et al. [4]
Yasukawa et al. [5]
Ethanol-ethyl acetate
extract (serotonin
derivatives and their
glucoside)
Immunomodulatory eﬀects mainly associated with
anti-inﬂammatory activities Takii et al. [6]
Serotonin derivatives
Antioxidant eﬀects mainly for prevention of atherosclerosis through
inhibition of LDL oxidation and postischemic myocardial
dysfunction
Koyama et al. [19]
Hotta et al. [20]
Trechelosides
Anabolic eﬀects and antiestrogenic activities on bone through
promotion of osteoblastic diﬀerentiation and inhibition of bone
resorption
Kim et al. [21]
Jang et al. [22]
Yoo et al. [23]
Yuk et al. [24]
Hong et al. [25]
Linoleate High linoleate in dietary oil supplements increase serum
concentrations of prostaglandin F2α metabolite Grant et al. [26]
Leaf
Flavonoids Antioxidative eﬀects Lee et al. [27]
Kinobeon A Ap r e v e n t i v ee ﬀect on singlet oxygen and acting as a tyrosinase
inhibitor
Kambayashi et al. [28]
Kanehira et al. [29, 30]
MHC-I and MHC-II) for antigen presentation, leading to
a strong immune response against foreign antigens [34].
TNF-α and CD40L can stimulate immature DCs to mature
in vitro and may show potential for clinical use [35],
suggesting that enhancement of DC maturation is required
for improvement of DC immunotherapy. In the clinic,
DC-based immunotherapies are being intensively studied
for their application in the treatment of certain diseases,
including cancer and infectious diseases [36–38]. Scientists
are trying to improve the phagocytic activity or antigen
presentation activity of DCs for use in immunotherapy [39,
40]. Certain herbal medicines can also improve DC function
[41]. To date, CT has been used as a folk medicine in cancer
adjuvant therapy, but its function has not been proven. In
this study, we studied the immunomodulatory eﬀects of CT
on cytokine secretion and surface immunologic molecules of
DCs in vitro and antitumor activities of CT-treated DCs in
an animal model of breast cancer.Evidence-Based Complementary and Alternative Medicine 3
300
250
200
150
100
50
0
IL-2 IL-4 IL-10
Cytokine
Control
IFN-γ
S
e
c
r
e
t
e
d
c
y
t
o
k
i
n
e
c
o
n
c
e
n
t
r
a
t
i
o
n
(
p
g
/
m
L
)
CT-5 μg/mL
CT-10 μg/mL
CT-20 μg/mL
Figure 1: CTextract stimulates cytokine secretion of mouse splenic
T lymphocytes. Splenocytes were homogenized from the spleen of
healthy BALB/c mice. Mouse splenic T lymphocytes were treated
with various concentrations of CT extract for 24h, and then the
medium was assessed for secretion of IL-2, IFN-γ, IL-4 and IL-10,
as determined by ELISA. The assay was performed in triplicate, and
the data are expressed as mean ± SE.
2.MaterialsandMethods
2.1. Cell Cultures and Reagents. JC cells (mouse mammary
adenocarcinoma) were purchased form American Type Cul-
ture Collection (ATCC, USA) and cultured in MEM medium
(Gibco, Invitrogen Inc., USA) supplemented with 10% fetal
bovine serum (FBS) (Hyclone, USA). GM-CSF and IL-4
were purchased from the PeproTech Inc. (NJ, USA). Phy-
coerythrin (PE)-hamster antimouse CD80 (B7-1) (16-10A1
clone, Cat No. 553769), ﬂuorescein isothiocyanate (FITC)-
rat antimouse CD86 (B7-2) (GL1 clone, Cat. No. 553691),
PE-mouse antimouse H-2Kd (MHC-I) (SF1-1.1 clone, Cat.
No. 553566) and FITC-mouse antimouse I-Ad (MHC-II)
(AMS-32.1 clone, Cat No. 553547) were purchased from
Becton Dickinson-Pharmingen (NJ, USA). FITC-anti-CD3
and PE-anti-CD8 were purchased from Becton Dickinson-
Pharmingen. To prepare the CT plant extract used in our
experiments, the ﬂowers of the plants were collected and
dried. Dried ﬂowers (100g) were boiled in 1l distilled water
(1:10 ratio, w/v) for 1h and the extract was ﬁltered through
Whatman No. 1 ﬁlter paper (Whatman, USA). The ﬁltrate
was lyophilized into powder and stored at 4◦C. The CT
powder was dissolved in phosphate-buﬀered saline (PBS)
(pH 7.4) at a stock concentration of 100mg/mL for in vitro
experiments.
2.2. Cytokine Secretion from Mouse Splenocytes Induced by CT
Extract. The splenocytes were homogenized from the spleen
of healthy BALB/c mice, and the splenic T lymphocytes were
isolated by passage through nylon wool columns [42]. The
purity of T cells was conﬁrmed by ﬂow cytometry to be
>90%. The mouse splenic T lymphocytes were treated with
various concentrations of CT extract (5, 10 and 20μg/mL
of culture medium) for 24h. The medium was collected to
determine the concentrations of the cytokines IL-2, IFN-γ
and IL-4. Cytokine levels were determined by the DuoSet
ELISA kit as described in the manual.
2.3. Maturation of Mouse DCs by CT Extract. Bone marrow
cells were taken from BALB/c mice and then suspended in
RPMI-1640 medium containing 10% FBS. The cell suspen-
sion was allowed to stand at room temperature for 10min
to remove the cell clots, and then the cell suspension was
centrifuged at 800g for 5min at 4◦C and washed with PBS
(pH 7.4) containing 0.5% FBS and 2mM EDTA. The cells
were allowed to attach to a 100-mm culture plate for 2h and
the ﬂoating cells were removed gently. The cells were then
treated with GM-CSF (100ng/mL) and IL-4 (100ng/mL) at
37◦C, 5% CO2 for 6 days, following the modiﬁcations of
Zhengetal.[43].After6daysofdiﬀerentiation,theDCswere
treated with various concentrations of CT extract (5, 10 and
20μg/mL of culture medium) for 72h. After CT treatment,
theDCswerecollectedforﬂowcytometricanalysisofsurface
immunological molecules (CD80, CD86, MHC-I and MHC-
II). In brief, the cells were stained with the speciﬁc FITC-
conjugated antibody.
2.4. Isolation of CD117+ Bone Marrow Cells. Bone marrow
cells were collected as above and suspended in PBS (pH 7.4)
containing 0.5% FBS and 2mM EDTA prior to the isolation
of CD117+ cells. CD117+ cells were isolated using magnetic-
activated cell sorting (Miltenyi Biotec Inc, CA, USA) as
described in the manual. Brieﬂy, 1 × 107 c e l l sw e r ea d d e d
to 20μl anti-CD117+ provided by the kit for 15min and
then washed with PBS to remove excess unbound antibodies.
The treated cells were loaded on a column, from which the
CD117− c e l l sw e r ee l u t e dw i t hP B Sb u ﬀer in the presence of
a magnetic ﬁeld. The CD117+ cells were then eluted in the
absence of a magnetic ﬁeld and were then diﬀerentiated to
DCs by adding GM-CSF and IL-4 as described above.
2.5. Generation of CD117+-Derived DCs. The CD117+ cells
were cultured at a density of 6.25 × 107/ w e l lo fa6 -
well plate in RPMI-1640 medium containing 10% FBS,
1.5mg/mL sodium bicarbonate, 0.1μmol/mL nonessential
amino acids, 1μmol/mL sodium pyruvate, 100 U/mL peni-
cillin G and 100μg/mL streptomycin supplemented with
GM-CSF (100ng/mL) and IL-4 (100ng/mL) at 37◦C, 5%
CO2 for 6 days. Medium containing GM-CSF and IL-4 was
refreshed every 2 days.
2.6. Assessment of Cytokines Released from JC Lysate-Pulsed
CT-Treated CD117+-Derived DCs. After diﬀerentiation of
CD117+ cells to DCs for 6 days, DCs were pulsed with JC-
lysate and treated with or without CT extract (5, 10 and
20μg/mL)foranadditional3days.Theconditionedmedium
was collected for determination of the concentrations of IL-
2, IL-10, TNF-α and IL-1β [44].
2.7. Assessment of Immunological Molecules of JC Lysate-
Pulsed CT-Treated CD117+-Derived DCs. After diﬀerentia-
tion of CD117+ cells to DCs for 6 days, DCs were pulsed with4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: CT extract enhances the maturation of mouse DCs.
Mouse bone marrow cells were collected as described in Section 2.
After 6 days of diﬀerentiation with GM-CSF and IL-4, the cells were
treated with various concentrations of CT extract in the absence
of GM-CSF and IL-4 for an additional 48 h. The cells were then
scraped and collected for surface molecule analysis (CD80, CD86,
MHC-I and MHC-II) using ﬂow cytometry.
JC lysate and treated with or without CT extract (20μg/mL)
for an additional 72h. After CT treatment, DCs cell were
analyzed for cell surface markers (CD80, CD86, MHC-I and
anti-MHC-II) by ﬂow cytometry.
2.8. Preparation of DC Vaccine and JC Tumor Animal Experi-
ment. CD117+ cells were cultured in diﬀerentiationmedium
(GM-CSF and IL-4) for 6 days followed by cultivation in
fresh RPMI medium in the presence or absence of CT
(20μg/mL) for 3 days. JC cells (3-4 × 106)w e r el y z e di n
1mL RPMI-1640 medium containing 10% FBS by freezing
and thawing four times, and the lysate was stored at –80◦Ca s
at u m o ra n t i g e nr e s o u r c e[ 45] to pulse the DCs.
BALB/c female mice (4–6 weeks) were purchased from
the National Laboratory Animal Center (Taiwan, ROC).
JC cells (3 × 106 per 150μl PBS) were subcutaneously
inoculated in the ﬂank of BALB/c mice. Twenty-four tumor-
bearing mice were grouped (n = 8/group) as follows:
untreated control, DC vaccine and CT-treated groups. In the
DC vaccine group and CT-treated DC vaccine group, mice
were injected intraperitoneally with the JC-pulsed DC cell
suspension (1.7 × 106 per 0.2mL PBS) and the CT-treated
JC-pulsed DC cell suspension (1.7 × 106 per 0.2mL PBS) on
day 13, respectively. The tumor growth of JC tumor-bearing
micewasmeasuredbyacaliperevery4–6daysandcalculated
using the equation, tumor weight (mg) = length (mm) ×
width (mm2)/2, until the tumor reached 2 × 103 mm3.O n
day 32, mice were euthanized by CO2, the tumors were
excised and weighed and the spleens of each mouse were
homogenized into a single cell suspension pulsed with or
without CT-treated DCs to measure Th1- and Th2-related
cytokines. The splenocytes were also re-stimulated with
the previous corresponding JC-pulsed DC vaccine and CT-
treated JC-pulsed DC vaccine for ﬂow cytometric analysis of
cytotoxicTlymphocytes.Allmicereceivedhumanecare,and
thestudyprotocolfollowedtheguidelinesoftheInstitutional
Animal Care and Use Committees of the Development
Center for Biotechnology (accredited by AAALAC).
2.9. Eﬀects of CT-Treated DCs on the Cytokine Secretion and
Cytotoxic T Lymphocytes of Mouse Splenocytes. DC vaccine
was prepared as described above and cultured in AIM-V
medium (Gibco, USA), and splenic T lymphocytes were
taken from the normal and the JC tumor-bearing mice and
cultured in RPMI-1640 medium (Gibco, USA). In brief,
splenic T lymphocytes were partially puriﬁed using a nylon
wool column [46]. Diﬀerent cytokines in response to CT
(20μg/mL)-treated DCs were determined when DCs (2 ×
105/mL) were pulsed with splenocytes from tumor-bearing
mice at a cell:cell ratio of 1:10, 1:20 and 1:40 for 48h
at 37◦C, 5% CO2. After cocultivation of splenocytes and
DCs, the medium was collected and stored at –20◦Cp r i o r
to cytokine analysis. Cytokines were analyzed by ELISA as
described above. The splenocyte culture was continued for
an additional 72h and then subjected to ﬂow cytometric
analysis, in which speciﬁc T lymphocytes were gated by
staining with FITC-anti-CD3 and PE-anti-CD8.
2.10. Statistical Analysis. Data were analyzed by one-way
ANOVA using SPSS statistical software followed by the
Dunnett’stestformultiplecomparisonsbetweeneachgroup.
A P-value < .05 was considered to indicate a signiﬁcant
diﬀerence.
3. Results
3.1. IFN-γ and IL-10 Secretion from Mouse Splenic T
Lymphocytes. To determine the eﬀect of CT extract on the
stimulation of mouse resting T lymphocytes, the splenic T
lymphocytes were partially puriﬁed and treated with various
concentrations of CT extract for 24h. The supernatants were
collected and evaluated for the levels of IL-2, IFN-γ and IL-
4 and IL-10. Figure 1 shows that CT extract stimulated the
production of IL-10 > IFN-γ in a dose-dependent manner
(Figure 1). However, no such stimulation was observed for
IL-2 and IL-4.
3.2. Expression of Immunological Molecules in the Immature
DCs. To determine whether the CT extract stimulated the
maturation of DCs, mouse bone marrow cells were isolated
and diﬀerentiated into immature DCs by adding GM-CSF
a n dI L - 4f o r6d a y s .T h ei m m a t u r eD C sw e r et r e a t e dw i t h
various concentrations of CT extract (5, 10 and 20μg/mL)
for 48h. Figure 2 shows that CT extract promoted the
expression of DC surface markers (CD86 < MHC-I = MHC-
II = CD80) in a dose-dependent manner (Figure 2).
3.3. Enhancement of Maturation of DCs by CT Extract. To
study whether the pattern of cytokine secretion was altered
in DCs stimulated by CT extract in the presence of tumorEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: CT extract enhances the maturation of CD117+-derived DCs in the presence of tumor antigen. Mouse bone marrow cells were
collected as described in Section 2.A f t e r6d a y so fd i ﬀerentiation with GM-CSF and IL-4, the cells were pulsed with JC tumor lysate (1.7 ×
106 per 0.2mL PBS; DC + JC) and treated with various concentrations of CT extract (5, 10, and 20μg / m L ;D C+J C+C T - 5 ,D C+J C+
CT-10 and DC + JC + CT-20) in the absence of GM-CSF and IL-4 for additional 48h. The medium was collected, and the concentrations of
secreted cytokines were determined. Data from triplicate points are expressed as the mean ± SE. Statistical analysis was performed by one-
way ANOVA followed by Dunnett’s test. A P-value <. 05 was considered to reﬂect a signiﬁcant diﬀerence. ∗P<. 05 , ∗∗P<. 01, ∗∗∗P<. 001.
antigens, the immature DCs were pulsed with JC tumor
lysate along with diﬀerent concentrations of CT extract (5,
10 and 20μg/mL) for 48h. The conditioned medium was
analyzed for IL-2, IL-10, TNF-α and IL-1β by ELISA and
the DCs were subjected to analysis of surface immunological
molecules (CD80, CD86, MHC-I and MHC-II). The results
showed that CT extract increased TNF-α and IL-1β levels in
a dose-dependent manner (Figure 3). However, the level of
IL-2 was reduced when DCs were pulsed with tumor lysate.
IL-10 decreased with an increase in the concentration of
CT extract, suggesting that CT extract might increase the
secretion of TNF-α and IL-1β to enhance the maturation of
immature DCs. Treatment with CT extract maintained the
high proﬁle of cell surface markers, such as CD80, CD86,
MHC-I and MHC-II on the CD117+-derived CDs in the
presence of tumor antigen (Figure 4).
3.4. Inhibition of Tumor Growth by CT Treated-DC Vaccine.
To study the antitumor activity of CT-treated DC vaccine,
BALB/c mice were inoculated with JC tumor cells and
challenged with a single dose of CT-treated DC vaccine. The
JCtumor-bearingmicewerechallengedwithDCvaccineand
CT-treated DC vaccine on day 13, when tumor reached the
size of 5mm (length) × 5mm (width). Results showed that
CT-treated DC vaccine and DC vaccine decreased the tumor
mass by 32.5% and 17.2%, respectively, compared to the
untreated control (Figure 5). This result suggested that CT
might increase the antitumor activity of the DC vaccine.6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: CT extract enhances the maturation of CD117+-derived
DCs. CD117+ cells were isolated as described in Section 2 and
then cultured in diﬀerentiation medium (GM-CSF and IL-4).
After 6 days of diﬀerentiation, the diﬀerentiated cells (D6) were
pulsed with JC tumor lysate (1.7 × 106 per 0.2mL PBS) in the
absence of diﬀerentiation cytokines for additional 72h (D9) or
pulsed with JC tumor lysate and incubated with 20μg/mL CT
for additional 72h (D9-CT). The CD117+-derived DCs were then
collected and analyzed by ﬂow cytometry for the expression of
surface immunological molecules. Experiments were performed in
triplicate, and the data are expressed as mean ± SE.
3.5. Polarization of Cytokine Secretion to Th1 Response. To
determine the Th1 and Th2 cytokine secretion in DC vaccine
treatment, the tumor-bearing mice that had been challenged
with DC vaccine were sacriﬁced and their splenocytes
subjected to cytokine analysis, in which those cells were re-
stimulated with the previous corresponding DC vaccine or
CT-treated DC vaccine ex vivo. Splenocytes of the CT/DC
vaccine compared with those of the CT-untreated DC-
vaccine showed increased or identical production of IL-2,
IL-10 and IFN-γ. However, IL-4 production was notably
decreased in splenocytes of mice treated with the CT/DC
vaccine (Figure 6). The secretion of cytokines was not
increased in the sham splenocytes when those cells pulsed
with DC vaccine or CT-treated DC vaccine with lack of JC
antigen. This result suggested that either the DC vaccine or
CT-treated DC vaccine elicited antitumor activity through a
Th1 response, and that CT extract might also enhance the
immune response of the DC vaccine.
3.6. Increased Antitumor Activity Is Mediated by Cytotoxic
TL y m p h o c y t e s . To determine whether cytotoxic T lympho-
cytes were increased in the CT-treated DC vaccine, the
splenocytes of vaccine-challenged mice were re-stimulated
with the previous corresponding DC vaccine or CT-treated
DC vaccine. The JC tumor lysate-pulsed DC vaccine stimu-
lated 30.1% of cytotoxic T lymphocytes and the JC tumor
lysate-pulsed CT-treated DC vaccine stimulated 35.6% of
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Figure 5: Antitumor activity of the CT extract-treated DC vaccine
in JC tumor-bearing mice. DC vaccine or CT-treated DC vaccine
(DC-CT) was administered via intraperitoneal injection on day 13
when mean estimated tumor weight was >63mg (0.5 × 0.5cm in
diameter). A group of tumor-bearing animals without treatment
was the tumor control. Animals were sacriﬁced on day 32, and the
tumors were excised and weighed. Data are expressed as mean ± SE
(n = 8 in each group).
cytotoxic T lymphocytes (Figure 7), indicating that CT-
treated JC tumor lysate-pulsed DC vaccine could increase
more cytotoxic T lymphocytes against tumors than DC
vaccine without CT treatment. Additionally, the cytotoxic T
lymphocytes of sham mice were only stimulated 27.6% with
CT-treated DC vaccine in the absence of JC tumor antigens.
This result was consistent with the decrease in tumor weight
shown in Figure 5.
4. Discussion
DCs are professional antigen-presenting cells that have
been enlisted for use in vaccines against cancer. DCs
can acquire tumor antigens by cocultivation with tumor
cells or pulsation with tumor lysates to become activated.
After maturation, the DCs present the tumor antigens to
lymphocytes and trigger the immune response cascade. In
this study, CT stimulated splenic T lymphocytes to secrete
IFN-γ and IL-10, suggesting that CT can immunomodulate
T lymphocyte function. Heightened expressions of CD80,
CD86, MHC-I and MHC-II imply that CT stimulates mat-
uration of antigen-presenting cells; moreover, an increase in
the expression of MHC-I and II molecules, together with an
increaseinCD8-positiveTcells,suggeststhatHLA-mediated
presentation of tumor antigens accelerates after treatment
with CT extract. CT also improved the antitumor activity of
the DC vaccine as evidenced by a reduction in tumor weight.
The ex vivo analysis of cytokine secretion and lymphocyte
populationsuggestedthatCTpolarizestheimmuneresponse
toward the Th1 pathway by increasing the secretions of IL-2
and IFN-γ, but not IL-4, and consequently produces more
cytotoxic T lymphocytes to elicit antitumor activity than
DC vaccine without CT treatment. It has been reported that
stimulated DCs secrete TNF-α,I L - 1 β and IL-10 during theEvidence-Based Complementary and Alternative Medicine 7
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Figure 6: Secretion of cytokines from mouse splenocytes re-stimulated with CT extract-treated DC vaccine ex vivo. Spleens from sham
(sham-spl) and tumor-bearing (JC-spl) BALB/c mice challenged with DC vaccine or CT-treated DC vaccine were taken and homogenized
into single cell suspensions. The splenocytes were cocultured with DC vaccine or CT-treated DC at cell:cell ratios of 10:1, 20:1 and 40:1
for 48h. The concentrations of secreted cytokines were determined by ELISA as described in Section 2.
maturation process and then polarize the T lymphocytes
toward the Th1 pathway [47], which is consistent with our
observations shown in Figure 3.
DCs are widely distributed in the human body with
diﬀerent morphologies, such as Kupﬀer cells in liver [48]
and Langerhans cells in the skin [49]. Unlike chemotherapy
w h i c hp r o d u c e ss e v e r es i d ee ﬀects during treatment, the
use of DCs provides an alternative strategy against tumors
[50]. The functions of DCs are improved in such as the
maturation, antigen presentation and regulatory cytokine
secretion, which has survival beneﬁts in cancer patients [51].
Although the CT-treated DC vaccine was intraperitoneally
injected to activate immunity in this study, oral admin-
istration of CT extract might promote the recognition of
antigens and facilitate antigen presentation via intestinal
DCs, and thus this attractive approach is worthy of further
investigation. However, many traditional medicinal herbals
have being studied for immunomodulatory activities, such
asMelilotussuaveolensLedeb[52]andTanacetumparthenium
[53]. In literatures, both herbal plants were found to demon-
strate their anti-inﬂammation activities in a monocytic cell-
based assay system and exhibited eﬀects on regulating the
production of chemokines. Due to these recent studies,
M. suaveolens Ledeb [52]a n dT. parthenium have been8 Evidence-Based Complementary and Alternative Medicine
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Figure 7:ExvivostimulationofspeciﬁcTlymphocytes.Thespleens
of sham and tumor-bearing mice were taken and homogenized
into single-cell suspensions. The splenocytes were re-stimulated
with their corresponding treatments (DC vaccine or CT-treated
DC vaccine) for 5 days. The splenocytes were then subjected to
ﬂow cytometric analysis, and speciﬁc T lymphocytes were gated by
staining with FITC-anti-CD3 and PE-anti-CD8.
implicated to exhibit potential therapeutic beneﬁts in treat-
ing many inﬂammation-related diseases, such as cancers,
atherosclerosis and rheumatoid arthritis. Therefore, herbals
in treating cancers might have activities via the modulation
of cytokine proﬁles. In this article, our results suggest that
CT could promote immunity through the activation of
DCs per se that do not alter the cytokine secretion during
immune responses of tumor lysate-pulsed DCs toward the
Th1 pathway.
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